miR-208-3p promotes hepatocellular carcinoma cell proliferation and invasion through regulating ARID2 expression
MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at post-transcriptional level. miRNA dysregulation plays a causal role in cancer progression. In this study, miR-208-3p was highly expressed and directly repressed ARID2 expression. As a result, ARID2 expression in...
Gespeichert in:
Veröffentlicht in: | Experimental cell research 2015-08, Vol.336 (2), p.232-241 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | MicroRNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression at post-transcriptional level. miRNA dysregulation plays a causal role in cancer progression. In this study, miR-208-3p was highly expressed and directly repressed ARID2 expression. As a result, ARID2 expression in hepatocellular carcinoma (HCC) was decreased. In vitro, miR-208-3p down-regulation and ARID2 over-expression elicited similar inhibitory effects on HCC cell proliferation and invasion. In vivo test results revealed that miR-208-3p down-regulation inhibited HCC tumorigenesis in Hep3B cells. Moreover, ARID2 was possibly a downstream element of transforming growth factor beta1 (TGFβ1)/miR-208-3p/ARID2 regulatory pathway. These findings suggested that miR-208-3p up-regulation is associated with HCC cell progression and may provide a new target for liver cancer treatment.
•miR-208-3p was highly expressed and directly repressed the expression of ARID2 in HCC.•miR-208-3p contributed to HCC cell progression both in vitro and in vivo.•Over-expression of ARID2 inhibited the HCC cell proliferation and invasion.•Restoration of ARID2 partly reversed the the effect of miR-208-3p down-regulation on HCC cells.•Newly regulatory pathway: miR-208-3p mediated the repression of ARID2 by TGFβ1 in HCC cells. |
---|---|
ISSN: | 0014-4827 1090-2422 |
DOI: | 10.1016/j.yexcr.2015.07.008 |